| The MutT proteins or “Nudix” hydrolases, a family of versatile, widely distributed,“housecleaning” enzymes MJ Bessman, DN Frick, SF O'Handley Journal of Biological Chemistry 271 (41), 25059-25062, 1996 | 808 | 1996 |
| Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug E Mastrangelo, M Pezzullo, T De Burghgraeve, S Kaptein, B Pastorino, ... Journal of Antimicrobial Chemotherapy 67 (8), 1884-1894, 2012 | 479 | 2012 |
| DNA primases DN Frick, CC Richardson Annual review of biochemistry 70 (1), 39-80, 2001 | 468 | 2001 |
| PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus … AM Lam, E Murakami, C Espiritu, HMM Steuer, C Niu, M Keilman, H Bao, ... Antimicrobial agents and chemotherapy 54 (8), 3187-3196, 2010 | 206 | 2010 |
| The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target DN Frick Current issues in molecular biology 9 (1), 1, 2007 | 185 | 2007 |
| Studies on the ADP-ribose pyrophosphatase subfamily of the nudix hydrolases and tentative identification of trgB, a gene associated with tellurite resistance CA Dunn, SF O'Handley, DN Frick, MJ Bessman Journal of Biological Chemistry 274 (45), 32318-32324, 1999 | 180 | 1999 |
| Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase AMI Lam, DN Frick Journal of virology 80 (1), 404-411, 2006 | 163 | 2006 |
| Understanding helicases as a means of virus control DN Frick, AMI Lam Current pharmaceutical design 12 (11), 1315-1338, 2006 | 145 | 2006 |
| The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently DN Frick, RS Rypma, AMI Lam, B Gu Journal of Biological Chemistry 279 (2), 1269-1280, 2004 | 145 | 2004 |
| Development of novel therapies for hepatitis C SM Lemon, JA McKeating, T Pietschmann, DN Frick, JS Glenn, ... Antiviral research 86 (1), 79-92, 2010 | 132 | 2010 |
| Discovering new medicines targeting helicases: challenges and recent progress WR Shadrick, J Ndjomou, R Kolli, S Mukherjee, AM Hanson, DN Frick Journal of biomolecular screening 18 (7), 761-781, 2013 | 127 | 2013 |
| Solution structure of the MutT enzyme, a nucleoside triphosphate pyrophosphohydrolase C Abeygunawardana, DJ Weber, AG Gittis, DN Frick, J Lin, AF Miller, ... Biochemistry 34 (46), 14997-15005, 1995 | 117 | 1995 |
| Cloning, Purification, and Properties of a Novel NADH Pyrophosphatase: EVIDENCE FOR A NUCLEOTIDE PYROPHOSPHATASE CATALYTIC DOMAIN IN MutT-LIKE ENZYMES (∗) DN Frick, MJ Bessman Journal of Biological Chemistry 270 (4), 1529-1534, 1995 | 115 | 1995 |
| Molecular basis for ADP-ribose binding to the Mac1 domain of SARS-CoV-2 nsp3 DN Frick, RS Virdi, N Vuksanovic, N Dahal, NR Silvaggi Biochemistry 59 (28), 2608-2615, 2020 | 109 | 2020 |
| DNA damage alters DNA polymerase δ to a form that exhibits increased discrimination against modified template bases and mismatched primers X Meng, Y Zhou, S Zhang, EYC Lee, DN Frick, MYWT Lee Nucleic acids research 37 (2), 647-657, 2009 | 98 | 2009 |
| Solution Structure of the Quaternary MutT−M2+−AMPCPP−M2+ Complex and Mechanism of Its Pyrophosphohydrolase Action, J Lin, C Abeygunawardana, DN Frick, MJ Bessman, AS Mildvan Biochemistry 36 (6), 1199-1211, 1997 | 93 | 1997 |
| Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication S Mukherjee, WS Weiner, CE Schroeder, DS Simpson, AM Hanson, ... ACS chemical biology 9 (10), 2393-2403, 2014 | 90 | 2014 |
| Orf186 represents a new member of the Nudix hydrolases, active on adenosine (5′) triphospho (5′) adenosine, ADP-ribose, and NADH SF O'Handley, DN Frick, CA Dunn, MJ Bessman Journal of Biological Chemistry 273 (6), 3192-3197, 1998 | 90 | 1998 |
| A Novel GDP-Mannose Mannosyl Hydrolase Shares Homology with the MutT Family of Enzymes (∗) DN Frick, BD Townsend, MJ Bessman Journal of Biological Chemistry 270 (41), 24086-24091, 1995 | 90 | 1995 |
| Helicases as antiviral drug targets DN Frick Drug news & perspectives 16 (6), 355, 2003 | 89 | 2003 |
Angela LamArbutus BiopharmaVerified email at arbutusbio.com